Ligands belonging to the transforming growth factor (TGF) ␤ ␤ superfamily have emerged as major regulators of a wide variety of developmental events, ranging from the earliest steps in germ layer patterning of the pre-gastrula embryo to tissue healing, regeneration and homeostasis in the adult. Recently, Caroline Hill and Bob Lechleider organized the third in a bi-annual series of FASEB meetings on TGF␤ ␤ signaling and development at Snowmass (CO, USA). This meeting highlighted the ongoing interplay between advances in our understanding of the molecular biology of TGF␤ ␤ family signaling and in investigations into its roles in specific developmental events.
Introduction
Since their identification in 1995, the Smad proteins have emerged as the major transducers of the TGF␤ signaling pathway, which regulates transcription during embryogenesis and adulthood ( Fig. 1) (Massague and Wotton, 2000) . Although important responses to TGF␤ signaling can occur both without Smads (Derynck and Zhang, 2003) and without transcriptional regulation (Ozdamar et al., 2005) , the predominant focus of this meeting was on mechanisms that regulate Smad activity and on how these mechanisms confer specific transcriptional responses. This emphasis arose largely from the sheer number and variety of candidate regulators and targets of Smad function that have been identified over the past few years (Fig. 1, Table 1 ) (Derynck and Zhang, 2003; ten Dijke and Hill, 2004) . A second focus of the meeting concerned how the TGF␤ ligand superfamily are extracellulary regulated (Fig. 2) . It has been well recognized for many years that a complex set of extracellular antagonists and co-factors modulate TGF␤ ligand activity. How these regulators fit together to generate spatially and temporally complex patterns of highly specific gene activation remains a crucial area of investigation. A number of talks reported on novel mechanisms of ligand regulation, some of which were placed in specific developmental contexts.
Transcriptional regulation by Smads: targets and cofactors
Numerous efforts have identified individual examples of promoters or enhancers that are regulated by the interaction of the Smads with tissue-specific transcription factors (e.g. Chen et al., 1996 , Seone et al., 2004 ) (reviewed by Massague and Wotton, 2000) , which have laid the basis for a more systematic analysis of sets of transcriptional responses to TGF␤. Several talks explored the problem of identifying synexpression sets of transcriptional responses to TGF␤ signals (synexpression sets are sets of genes that are coordinately expressed in response to a given stimulus). Joan Massague (Sloan-Kettering Institute, New York, NY, USA) built on prior work from his laboratory that established the Foxo transcription factors as being Smad3 interactors (Seoane et al., 2004) . At this meeting, he reported on the transcriptional profiling of Foxo-null cells to identify transcriptional responses that are specifically mediated by Smad3/Foxo interactions. Analysis of Smad3/Foxo responsive elements from several target genes, such as p21CIP1 (Cdkn1a -Mouse Genome Informatics) (Seoane et al., 2004) , revealed considerable diversity in the spatial relationship between Smad-and Foxo-binding sites, thus indicating relatively loose constraints on how complexes of these factors recognize target promoters. Liliana Attisano (University of Toronto, Toronto, Canada) presented an in silico approach to identifying the targets of Foxh1, a transcription factor that associates with activated Smad2/Smad4 complexes during patterning of early embryos by the nodal subset of TGF␤ ligands (Chen et al., 1996) . By combining information on the genomic location of predicted DNA-binding sites for Foxh1 and Smad4 with crossspecies comparisons, these investigators identified and validated several novel embryonic targets of Foxh1 signaling.
Aristidis Moustakas (Ludwig Institute, Uppsala, Sweden) focused on responses that either coordinate or distinguish TGF␤ effects on epithelial-to-mesenchymal transitions (EMTs) and on inhibition of cell proliferation. He described the functional characterization of genes identified in a broadly targeted microarray screen that compared genes that are induced by TGF␤ in NMuMg mammary epithelial cells (in which TGF␤ concomitantly induces cytostasis and EMT) with those that are induced by Bmp7 (which induces neither response in these cells). Members of the Id family of basic helix-loop-helix (bHLH) factors, particularly Id2, emerged from this study as being crucial targets for the downregulation of gene expression by TGF␤ during the regulation of both cytostasis and EMT. Two additional gene targets of TGF␤ signaling were identified: a high-mobility group protein, which acts as a potential upstream regulator of EMT; and a homeodomain protein, which regulates the epithelial cytostatic response.
Kunxin Luo (University of California, Berkeley, CA, USA) approached the issue of TGF␤-regulated transcription and EMT versus cytostasis from a different angle by examining the role of the co-repressors Sno and Ski in these processes. Sno and Ski have previously been shown by the Luo laboratory and others to act as co-repressors that interact with Smads to suppress TGF␤-stimulated transcription (Luo, 2004) . Although the functions of Sno and Ski have generally been viewed as being overlapping, Luo used RNAi analysis to show that their individual knock down produces distinctive effects on cell motility, EMT and growth arrest, suggesting that the relative endogenous levels of Sno and Ski may lead to distinctive responses to TGF␤ signals.
The differential interaction of Smad complexes with corepressors and co-activators is emerging as a major issue in mechanisms that generate specific cell-type responses to TGF␤ signals. Rik Derynck (University of California, San Francisco, CA, USA) touched on this issue for Smad3/Runx2 complexes, which interact with specific histone deacetylases (HDACs) to shut off bone-differentiation genes in mesenchymal stem cells. By contrast, Runx1 and Runx3 appear to form transcriptional activation complexes with Smads in other cell types (Ito and Miyazono, 2003) .
Although a wide range of transcriptional components that mediate TGF␤ signals have been identified, the mechanistic basis for transcriptional activation by Smads has not been directly examined. Caroline Hill (Cancer Research UK, London, UK) addressed this gap by establishing an in vitro assay for Smad-mediated transcriptional activation. This assay is likely to provide an important tool for understanding the specifics of how Smads interact with and modulate the local activity of the transcriptional machinery.
Distinct and overlapping Smad functions
Although functional distinctions between different Smads have been established in assays in vitro, the significance of these distinctions has been awaiting in vivo tests. Smad2 and Smad3 are regulated by similar upstream pathways ( Fig. 1 ) but differ biochemically in that Smad3 can bind directly to DNA, whereas Smad2 cannot, owing to an insert in the otherwise conserved DNA-binding region (Dennler et al., 1999) . This insert is excised in an alternative splice variant of Smad2 (Smad2␦ exon3), enabling it to bind DNA, but the significance of this splice variant in vivo is not known. Inactivation of the Smad3 gene in mice does not result in disruption of early embryogenesis, indicating that Smad2 can effectively compensate for Smad3 at these stages (Datto et al., 1999; Yang et al., 1999) . Liz Robertson (Oxford University, Oxford, UK) presented new evidence indicating that Smad2␦ exon3 can functionally substitute for both Smad3 and Smad2 when it is expressed in the mouse epiblast. Her genetic interaction data suggest that Smad3 can partially compensate for some Smad2 functions. Thus, the DNA-binding activities of Smad2␦ exon3 and Smad3 appear to be of crucial importance in the early mouse embryo. By contrast, Lalage Wakefield (National Cancer Institute, Bethesda, MD, USA) reported significant differences in how mammary epithelial cells that lack either Smad2 or Smad3 genes or proteins (?) respond to TGF␤. Thus, functional divergence between Smad2 and Smad3 seems to be a cell-context-dependent phenomenon, and defining the basis for this divergence will be an important area for further investigation. Findings from both the Robertson and Wakefield laboratories indicate that the level of Smads (as controlled by gene dose) is an important component of phenotypic outcome, consistent with work from many other laboratories demonstrating that the ubiquitin ligase-targeted degradation of Smads is an important mechanism of Smad regulation (Datto and Wang, 2005 The activation of FGF signaling was reported to be important for the TGF␤-induced proliferation of craniofacial bone development by Yang Chai (University of Southern California, Los Angeles, CA, USA). However, this TGF␤-FGF relay mechanism appears to be specific for the induction of bone formation from neural crest mesenchyme, as opposed to the induction of smooth muscle differentiation. Bob Lechleider (Georgetown University Medical Center, Washington, DC, USA) reported that it is downregulation of FGF signaling that is important for TGF␤-induced smooth muscle differentiation. The close intertwining of TGF␤ signaling with other pathways appears to be an important component of cell fate determination by TGF␤ family members.
Extracellular regulation of TGF␤ ligands
The extracellular regulation of TGF␤ ligand activity is an expanding area of investigation, and has been intensely investigated during Drosophila dorsoventral patterning. In Drosophila blastoderm embryos, extracellular BMP-binding proteins (Sog and Tsg) and the metalloprotease Tolloid are required to localize BMP activity to a narrow spatial domain at the dorsal midline of the late blastoderm embryo (reviewed by Ashe, 2005; Raftery and Sutherland, 2003) . Mike O'Connor (University of Minnesota, Minneapolis, MN, USA) presented his group's studies of the related extracellular DPP/BMPbinding proteins, Crossveinless2 (Cv2), Crossveinless (Cv) and Tolloid-related (Tlr), which are required to localize BMP activity to the narrow line of primordial wing cells in Drosophila where the posterior crossvein will form Serpe et al., 2005; Shimmi et al., 2005) . Differences in kinetics between the Sog/Tsg/Tolloid system and the Cv2/Cv/Tlr system correlate with the differences in temporal constraints for patterning in these two tissues. O'Connor described a bind and release mechanism for localizing active BMP ligands that almost certainly also occurs in vertebrate tissues because all three classes of extracellular regulators are also found in vertebrates: the Sog/CV/Chordin type of BMP-binding proteins; Tolloid/Tlr/BMP1 extracellular metalloproteases; and Tsg-like proteins (reviewed by Dale, 2000) .
Metalloproteases related to Tolloid are proving to be a versatile group of BMP regulatory proteins. Tolloid and its Xenopus homolog Xolloid have previously been shown to have similar abilities to cleave the BMP antagonists Sog and Chordin (reviewed by Mullins, 1998) . Each is now reported to release active TGF␤ family ligands by targeting a different class of latent complexes. Some TGF␤ ligands form latent complexes when the initially synthesized propeptide is cleaved during secretion; the C-terminal ligand domain remains associated with the N-terminal pro-domain in a latent complex (reviewed by Massague, 1998) . Malcolm Whitman (Harvard Dental School, Boston, MA, USA) reported that Xenopus GDF11, a TGF␤ ligand, is secreted as a latent complex of mature ligand and pro-domain. This complex is cleaved, so that GDF11 is activated by Xolloid in the developing tail, where these factors are co-expressed. Mihaela Serpe (University of Minnesota, Minneapolis, MN, USA) reported that Drosophila Tolloid and Tolloid-related both can activate latent ligands in a cell culture system. Murine Bmp1, another member of this family, can also activate latent ligands (Ge et al., 2005) . This class of metalloproteases has broad biological activities, as Bmp1 cleaves a number of extracellular matrix proteins in biologically important reactions (Gonzalez et al., 2005) . The ability of pro-domains to remain associated with the ligand in a secreted latent complex was first identified for TGF␤1, TGF␤2 and TGF␤3 (reviewed by Massague, 1998) . However, not all ligands in this family form such complexes; for example, there have been no reports of such complexes for Bmp2 and Bmp4. Intriguingly, Bmp9 appears to retain full biological activity, while it is associated with its prodomain (Senyon Choe, Salk Institute, San Diego, CA, USA). Perhaps the formation of pro-domain latent complexes is a characteristic of broadly expressed or circulating ligands, whereas ligands with more limited expression patterns might be regulated by other mechanisms.
Cell-surface co-receptors were highlighted at the meeting as another area of expanding significance. The importance of coreceptors for TGF␤ family signaling was recognized early on, with the identification of betaglycan as a cell surface protein that binds TGF␤ ligands and facilitates the activation of the signaling receptor complex (Lewis et al., 2000) . More recently, it has been found that cripto is an essential co-receptor for nodal signaling (reviewed by Schier, 2003) . Michael Shen (UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ, USA) discussed evidence for non-cell-autonomous functions of murine cripto (Yan et al., 2002) . Rick Padgett (Rutgers University, Piscataway, NJ, USA) presented the genetic identification of candidate co-receptors of the C. elegans sma pathway, and Jodie Babbitt (Massachusetts General Hospital, Boston, MA, USA) reported that RGMa, like other proteins in the Dragon family, is a co-receptor for BMPs (Babitt et al., 2005) .
The functional pairing of TGF␤ superfamily receptors to ligands, like functional divergence among the Smads, has been established in vitro but has not been fully investigated in vivo. TBRII and Alk5 have been identified as type II and type I receptors, respectively, for TGF␤. Yang Chai (University of Southern California, Los Angeles, CA, USA) and Vesa Kaartinen (Saban Research Institute, Children's Hospital, Los Angeles, CA, USA) presented data on the loss of T␤RII and Alk5, respectively, in neural crest derivatives in mice. In each case, dramatic craniofacial malformations result, consistent with the action of these receptors in a common neural crest pathway. Intriguingly, however, loss of Alk5 results in additional defects not seen with loss of the gene encoding T␤RII, raising the possibility that the Alk5 Type I receptor may act in conjunction with Type II receptors other than T␤RII in the developing neural crest.
TGF␤ signaling and vascular development
Studies of TGF␤ signaling in mouse angiogenesis have been informative both for uncovering novel mechanisms of TGF␤ signal transduction and for elucidating the etiology of vascular defects in human hereditary hemorrhagic telangiectasia (HHT) (reviewed by Marchuk et al., 2003) . HHT1 is associated with mutations in eng, the gene for endoglin. HHT2 is associated with mutations in ACVRL1, the gene for Alk1, a type I receptor that can bind TGF␤. Both syndromes are marked by the formation of direct arterial-venous malformations in some tissues, in which arteries and veins are directly connected with no intervening capillary network. These syndromes suggest that a sufficient level of TGF␤ signal transduction is necessary to maintain capillary networks in certain tissues. Consistent with this hypothesis, TGF␤ has dose-dependent effects on endothelial cells in vitro. Doug Marchuk (Duke University, Durham, NC, USA) presented the human genetic perspective on TGF␤ signaling. In addition to the two autosomal dominant HHT syndromes that have been described in humans, Marchuk reported that individuals with juvenile polyposis, which is associated with mutations in MADH4 (Smad4), also exhibit HHT-like lesions (Gallione et al., 2004) . It seems likely that these human syndromes identify rate-limiting steps for TGF␤ regulation of capillary remodeling.
There was lively discussion during the vasculogenesis session, as investigators sought to resolve the complex phenotypes observed in different studies of receptor mutants in murine endothelial cells. A substantial effort has been directed towards developing mouse genetic models of HHT, and towards understanding the mechanisms of TGF␤ signaling in (Massague, 1998; Dale, 2000; Ashe, 2005) . Activity can be modulated both positively and negatively by cell surface proteins, as discussed in the text. This figure provides a snapshot of systems discussed at the meeting, and is not intended to be a comprehensive review. Abbreviations: Sog, Short gastrulation, Tsg, Twisted gastrulation angiogenesis. In vitro studies of angiogenesis divide the process into two phases, both of which are stimulated by TGF␤1 (reviewed by Lebrin et al., 2005; Marchuk et al., 2003) . Vascular remodeling begins with endothelial cell migration, proliferation and lumen formation, which are aspects of the activation phase of angiogenesis. Remodeling is completed with the cessation of endothelial cell proliferation and migration, the production of new basement membrane, and the recruitment and differentiation of smooth muscle cells, i.e. the maturation, or resolution, phase of angiogenesis. Mice homozygous null for either Eng or Alk1 (Acvrl1 -Mouse Genome Informatics) have defects in the embryonic vasculature; initial vasculature formation occurs, but subsequent remodeling is defective (Li et al., 1999; Oh et al., 2000) . The effects of these mutations on angiogenesis in vivo and in embryonic endothelial cells are under intensive investigation.
TGF␤ can stimulate two Smad pathways in endothelial cells: the canonical Smad2/Smad3/Smad4 pathway via its predominant type I receptor, Alk5; and the Smad1/Smad5/Smad4 pathway via Alk1 (Fig. 3 ) (reviewed by Lebrin et al., 2005; Marchuk et al., 2003) . ten Dijke presented data that support an attractive model in which Alk1/Smad1 signaling promotes the activation phase of angiogenesis and Alk5/Smad2/Smad3 signaling promotes the resolution phase (Goumans et al., 2002) . However, this model may be incomplete, as Paul Oh (University of Florida, Orlando, FL, USA) and Sabine Bailly (INSERM, Grenoble, France) reported results indicating that Alk1 promotes maturation (Lamouille et al., 2002; Seki et al., 2003) . At present, it is not clear whether these conflicting results arise from the use of different endothelial cell types, or whether some of the effects observed arise from compensatory changes in constitutively mutant tissues. O'Connor reported embryonic vascular defects in Tak1 knockout homozygotes, raising the possibility that angiogenesis may also involve non-Smad signal transduction via this MEKK kinase.
Endoglin was identified soon after betaglycan as a potential endothelial component of TGF␤ receptor complexes; initial data suggested that it antagonizes TGF␤ signaling (Barbara et al., 1999) . ten Dijke reported that endoglin can promote signaling through Alk1 and antagonize signaling through Alk5; Jeff Wrana (Samuel Lunenfeld Institute, Toronto, Canada) touched on results that indicate that endoglin antagonizes signaling by regulating Alk5 levels (Lebrin et al., 2004; PeceBarbara et al., 2005) . The molecular mechanisms by which endoglin can bias receptor choice by TGF␤ ligands are still unclear. Understanding the mechanisms for receptor choice Fig. 3 . A model for TGF␤1 signal transduction during mouse angiogenesis. TGF␤1 can activate two type I receptors in cultured endothelial cells (reviewed by Byfield and Roberts, 2004) . As expected, it activates Alk5 (also called T␤RI), the canonical TGF␤ type 1 receptor, and surprisingly also Alk1, an orphan type 1 receptor that stimulates Smad1 phosphorylation, which is normally associated with BMP signaling (see Table 1 ). Different levels of TGF␤ promote different endothelial cell responses, supporting a model in which low signaling activity promotes activation responses and high signaling activity promotes resolution responses. The specific phase of angiogenesis regulated by Alk1 is controversial ('?'). The cell-surface protein endoglin reportedly stimulates Alk1 signaling and antagonizes Alk5 signaling (Lebrin et al., 2004; Pece-Barbara et al., 2005) through unclear mechanisms. Tak1 knockout mice have embryonic vasculature defects, suggesting that this non-Smad pathway is involved in TGF␤ signaling during angiogenesis. [For comprehensive discussions of this model, see Marchuk (Marchuk, 2003) and Lebrin et al. (Lebrin et al., 2005) .] Alk, activin receptor-like kinase; P, phosphate; Tak1, TGF␤ activated kinase 1; Txn Fac, transcription factor. 
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Plasma membrane Nucleus and the specific cell types that are most sensitive to each signal transduction pathway remain crucial issues for this field. These studies of TGF␤ signaling in mouse angiogenesis, like studies of BMP signaling in Drosophila patterning, underscore the importance of developmental genetics for uncovering the delicate balance of mechanisms that mediate dose-dependent responses to TGF␤ family ligands in normal development.
Conclusions
The TGF␤ field has made dramatic progress in the identification of components of the pathways that regulate TGF␤ signaling both extracellularly and intracellularly. The importance of in vivo developmental analyses to test these molecular mechanisms is highlighted by the evolving story on TGF␤1 signaling in angiogenesis. Similar studies of other in vivo mechanisms will be fertile ground for presentations in 2 years at the next meeting.
